Compare Cytokinetics Inc (CYTK) vs Workday Inc (WDAY) Price & Performance

Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.

Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.

Workday (WDAY) trades at $184.26, down 1.23% on the day, amid a broader tech selloff. The stock shows bearish technical signals with support at $182 and resistance at $187. Fundamentally, WDAY reported strong Q2 2026 EPS of $2.75, beating estimates, with revenue growth projected to reach $10.2B in 2026. Recent news includes strategic layoffs, AI product launches, and expansion in the UAE, highlighting its focus on enterprise AI solutions.

WDAY's outlook is supported by robust AI-driven revenue growth and a 50.6% analyst buy rating, with a consensus price target of $202.92 offering ~10% upside. Risks include integration costs from restructuring, competitive pressures in HR/finance software, and market volatility. The stock remains a compelling growth play if execution on AI monetization continues.